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A novel series of furoxan (1,2,5-oxadiazole 2-oxide) (compounds 3, 4a and -b, 13a and -b, and 14a to -f) and benzofuroxan
(benzo[c][1,2,5]oxadiazole 1-oxide) (compounds 7 and 8a to -c) derivatives were synthesized, characterized, and evaluated for in
vitro activity against promastigote and intracellular amastigote forms of Leishmania amazonensis. The furoxan derivatives ex-
hibited the ability to generate nitric oxide at different levels (7.8% to 27.4%). The benzofuroxan derivative 8a was able to in-
crease nitrite production in medium supernatant frommurine macrophages infected with L. amazonensis at 0.75 mM after 48 h.
Furoxan and benzofuroxan derivatives showed remarkable leishmanicidal activity against both promastigote and intracellular
amastigote forms. Compounds 8a, 14a and -b, and 14d exerted selective leishmanicidal activities superior to those of amphoteri-
cin B and pentamidine. In vitro studies at pH 5.4 reveal that compound 8a is stable until 8 h and that compound 14a behaves as a
prodrug, releasing the active aldehyde 13a. These compounds have emerged as promising novel drug candidates for the treat-
ment of leishmaniasis.
Leishmaniasis is caused by more than 20 species of the proto-zoan parasite Leishmania and is transmitted to humans by the
bite of infected female phlebotomine sand flies (1). The disease is
widely distributed in 98 tropical and subtropical countries and
poses amajor public health problem and a risk for people living in
or traveling to areas of endemicity. It has an annual estimated
worldwide incidence of 600,000 and a prevalence of 12 million
cases (2). Increased rates in patients coinfected by HIV and the
development of resistance to current drugs have transformed
leishmaniasis into a serious public health problem (3, 4).
This parasitic disease presents a wide range of clinical symp-
toms, characterized by cutaneous, mucocutaneous, or visceral
leishmaniasis which differs in immunopathologies and degrees of
morbidity andmortality. In humans, cutaneous leishmaniasis has
shown a wide spectrum of clinical manifestations which can vary
from localized cutaneous leishmaniasis to serious clinical forms
such as diffuse cutaneous leishmaniasis andmucocutaneous leish-
maniasis (5). In the New World, mainly Latin America, Leishma-
nia amazonensis is one of the main common infectious agents
responsible for these clinical manifestations (6, 7).
Despite current advances in understanding the molecular bi-
ology and biochemistry of the parasite, the first-choice treatment
of several forms of leishmaniasis remains focused on the use of the
obsolete pentavalent antimonials, such as sodium stibogluconate
and meglumine antimoniate (8). Pentavalent antimonials are
toxic and frequently ineffective, and their administration requires
medical supervision (9, 10). In addition, antimony resistance has
become commonduring leishmaniasis treatment (11, 12). On this
issue, in the last few decades efforts have been made to discover
alternative treatments. Amphotericin B (and its liposomal formu-
lations), pentamidine, paromomycin, and miltefosine are cur-
rently being used in leishmaniasis treatment as second choices.
However, these drugs are expensive and may be even more toxic
than antimonials (8, 13, 14).
Furoxan (1,2,5-oxadiazole 2-oxide) and benzofuroxan (benzo[c]
[1,2,5]oxadiazole 1-oxide) derivatives have been explored as
pharmacophores to design leishmanicidal drug candidates (15,
16).Hernándezandcoworkershave identifieda seriesof furoxanand
benzofuroxan derivatives active against L. amazonensis. The
compounds (E)-N=-(5-benzofuroxanylmethylidene)benzo[d][1,3]
dioxole-5-carbohydrazide and (E)-N=-(4-hydroxy-3-methoxyphe-
nylmethylidene)-3-methylfuroxan-4-carbohydrazide were less ac-
tive than amphotericin B; however, they were, respectively, 5- to
50-fold more selective than the reference drug in cytotoxicity
studies against murine macrophages (17) (Fig. 1). Boiani and co-
workers have described the evaluation of alkylnitrates and furoxan
derivatives against two promastigote forms of two Leishmania
species: Leishmania braziliensis and Leishmania pifanoi (18). Ben-
zofuroxanderivatives containing vinylthio, vinylsulfinyl, vinylsul-
fonyl, and vinylketo subunits have also demonstrated leishmani-
cidal activity superior to that of miltefosine against L. braziliensis
and L. pifanoi. However, despite the excellent activity, the benzo-
furoxan derivatives were not able to act as nitric oxide (NO) do-
nors, and these compounds have shown high cytotoxicity against
J-774 mouse macrophage cells (18).
The mechanism of action of benzofuroxan derivatives is not
totally understood. It was hypothesized that benzofuroxan deriv-
atives could produce oxygen/nitrogen reactive species in the par-
asite and inhibit mitochondrial dehydrogenases (15–18). On the
other hand, for furoxan derivatives it has been proposed that the
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N-oxide group seems to act as a bioreducible group in the parasite,
generating free radical species such as nitric oxide (NO). The
leishmanicidal activity of furoxan derivatives seems to be related
to the increase of nitric oxide levels, and the loss of activity by
furoxan derivatives without anN-oxide subunit is described else-
where (16–18). NO is a potent antimicrobial agent which helps to
eliminate intracellular pathogens. The Leishmania species, during
their different life stages, have variable sensibilities to reactive ox-
ygen species (ROS). After the recognition of the parasite, macro-
phages are activated to “effector cells” and trigger several oxidative
and immune responses to destroy the unwanted guest (19).More-
over, NO is able to interrupt the Leishmania life cycle by inactivat-
ing parasite enzymes such as cysteine proteinases. Specifically, NO
mediates chemical modification of the cysteine residue present in
the site of proteinases of Leishmania spp., blocking this enzyme
activity (20).
The N-acyl hydrazone (NAH) subunit has been described as a
privileged structure to design new compounds with different
pharmacological effects, including antiparasitic activity (17). Sev-
eral studies have demonstrated that this subunit is the pharmaco-
phoric group to develop cysteinyl protease inhibitors and that it
could contribute to improving the biological activity of the new
furoxan and benzofuroxan derivatives (21–23). Therefore, in a
continuing effort to develop new candidate drugs to treat leish-
maniasis, we report here the synthesis, NO donor ability, leish-
manicidal activity, and cytotoxic effect onmurine peritonealmac-
rophages of 15 furoxan (compounds 3, 4a and -b, 13a and -b, and
14a to -f) and benzofuroxan (compounds 7 and 8a to -c) deriva-
tives containing anN-acyl hydrazone subunit designed as antipa-
rasitic agents to treat this neglected disease.
MATERIALS AND METHODS
Chemistry. Melting points (mp) were measured with an electrothermal
melting point apparatus (SMP3; Bibby Stuart Scientific) in open capillary
tubes and are uncorrected. Infrared (IR) spectra (KBr disc)were produced
on an FTIR-8300 Shimadzu spectrometer, and the frequencies are ex-
pressed per cm. 1H nuclear magnetic resonance (NMR) and 13C NMR
spectra were scanned on a Bruker DRX-400 (400-MHz) NMR spectrom-
eter using CDCl3, dimethyl sulfoxide (DMSO)-d6, and acetoned6 as the
solvents. Chemical shifts were expressed in parts per million (ppm) rela-
tive to tetramethylsilane. The coupling constants are reported in hertz
(Hz), and signal multiplicities are reported as singlet (s), doublet (d),
doublet of doublet (dd), and multiplet (m). Mass spectrometry of all
compounds was performed with a model micrOTOF electrospray ioniza-
tion-time of flight (ESI-TOF) (Bruker Daltonics) spectrometer, and the
spectra were accumulated for 60 s. The compounds were injected at a flow
rate of 300 l/h, a capillary voltage of 4.5 kV, a cone voltage of 120 V, and
a desolvation temperature at 180°C. The spectra were obtained in positive
mode and acquired in the range of 200 to 800m/z. Elemental analyses (C,
H, and N) were performed on a PerkinElmer model 240C analyzer, and
the data were within0.4% of the theoretical values. High-pressure liq-
uid chromatography (HPLC) analysis was performed on a Shimadzu LC-
10AD chromatograph equipped with a model SPD-10A UV-visible (UV-
Vis) detector (Shimadzu). All compounds were analyzed by HPLC, and
their purity was confirmed to be greater than 98.5%. The compounds
were separated on a reversed-phase C18 (5-m particle, 250-mm by
4.6-mm inside diameter [i.d.]) Shimadzu Shim-Pack CLC-ODS (M) col-
umn. HPLC-grade solvents (acetonitrile, methanol, acetic acid, and tolu-
ene) were used in the analyses and were bought from a local supplier. The
progress of all reactions was monitored by thin-layer chromatography
(TLC), which was performed on 2.0- by 6.0-cm2 aluminum sheets pre-
coated with silica gel 60 (HF-254; Merck) to a thickness of 0.25 mm. The
developed chromatograms were viewed under UV light (265 nm) and
treated with iodine vapor. Merck silica gel (70/230 mesh) was used for
preparative column chromatography. Reagents and solvents were pur-
chased from commercial suppliers and used as received.
Compounds 2, 7, and 12 were synthesized according to a previously
described methodology (24–27). The compounds 2-, 3-, or 4-aminoben-
zohydrazide and 2-, 3-, or 4-hydroxybenzohydrazide were purchased
commercially.
Preparation of compound 3. A mixture of (2-oxido-4-phenyl-1,2,5-
oxadiazol-3-yl)methanol (compound 2) (0.4 g, 1.68 mmol), pyridinium
chlorochromate (0.37 g, 1.71 mmol), and 20 ml of dry dichloromethane
was stirred under nitrogen at 25°C for 24 h. Compound 3 was isolated by
the addition of 30ml ofwater. Then, the aqueous phasewas extractedwith
FIG 1 Chemical structures of some reported furoxan and benzofuroxan derivatives active against Leishmania species (13–15).
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chloroform (4 times, 40 ml each). The organic phase was dried with so-
dium sulfate or magnesium sulfate. After filtration, the organic phase was
concentrated under reduced pressure to produce brown oil. The samples
were further purified with silica gel column chromatography, using
hexane-ethyl acetate (6:4) as the mobile phase, producing compound 3 as
an oil.
Data for 4-phenyl-1,2,5-oxadiazol-3-carbaldehyde 2-oxide (com-
pound 3) are as follows: yield, 45%; infrared (IR) Vmax (cm
1; KBr
pellets), 3,059 (C-H aromatic), 2,827 (C-Haldehyde), 1,696 (CAO
imidealdehyde), 1,620 and 1,548 (CAN furoxan), 1,600 and 1,460 (CAC aro-
matic), 1,358 (N-O). 1H NMR (400 MHz, acetoned6) : 10.1 (1H; s), 7.97
(2H; m), 7.62 (3H; m) ppm. 13C NMR (100 MHz, acetoned6) : 115.78,
126.94, 128.32, 129.98, 131.95, 157.8, and 178 ppm. Analysis calculated
for C9H6N2O3: C, 56.85; H, 3.18; N, 14.73. Found: C, 56.3; H, 3.19; N,
14.5. Low-resolution mass spectrometry (LRMS):m/z 191.05 [MH].
General procedure for the synthesis of compounds 4a and b and 8a
to c. A mixture of 6-formyl-2,1,3-benzoxadiazol 1-oxide (compound 7)
(0.37 g, 2.25 mmol) or 4-phenyl-1,2,5-oxadiazol-3-carbaldehyde 2-oxide
(compound 3) (0.43 g, 2.25 mmol); 2-, 3-, or 4-aminobenzohydrazide
(0.32 g, 2.15mmol); and 8ml of anhydrous ethanol containing 5 drops of
glacial acetic acid was stirred at room temperature while protected from
light for 15 h. The reaction was monitored by TLC using hexane-ethyl
acetate (1:1) as themobile phase. The compounds 4a and b or 8a to c were
isolated by filtration and purified by crystallization using ethanol to pro-
duce yellow solids.
Data for 2-amino-N=-[(1E)-(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)
methylene]benzohydrazide (compound 4a) are as follows: yield, 48%;
melting point (mp), 190 to 192°C. Rf, 0.07 (1:1 ethyl acetate-hexane). IR
Vmax (cm
1; KBr pellets): 3,369 (N-H amine), 3,079 (C-H aromatic),
1,647 (CAO amide), 1,606 (CAN imine), 1,600 and 1,460 (CAC aro-
matic), 1,450 (N-O furoxan). 1HNMR(300MHz,DMSOd6) : 11.97 (1H;
s; N-H), 8.44 (1H; s; C-Himine), 7.76 (2H; dd; Jortho 7.8 Hz and Jmeta
1.5 Hz), 7.61 (2H; d; Jortho  7.8 Hz), 7.56 (1H; dt; Jortho  7.8 Hz and
Jmeta 1.5Hz), 7.48 (1H; d; Jortho 7.9Hz), 7.22 (1H; dd; Jortho 7.9Hz
and Jmeta 1.9Hz), 6.77 (1H; dd; Jortho 7.9Hz and Jmeta 1.9Hz), 6.58
(1H; d; Jortho 7.9 Hz), 6.45 (2H; s; N-Hamine) ppm.
13C NMR (75MHz,
DMSOd6) : 165.2, 156.58, 148.7, 132.90, 131.76, 129.62, 129.31, 128.30,
126.90, 124.92, 121.7, 118.82, 116.40, 113.7 ppm. Analysis calculated for
C16H13N5O3: C, 59.44; H, 4.05; N, 21.66. Found: C, 59.38; H, 4.27; N,
21.53. LRMS: m/z 324.10 [MH].
Data for 4-amino-N=-[(1E)-(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)
methylene]benzohydrazide (compound 4b) are as follows: yield, 50%;
mp, 209 to 212°C. Rf, 0.3 (1:1 ethyl acetate-hexane). IR Vmax (cm
1; KBr
pellets): 3,470 (N-H amine), 3,082 (C-H aromatic), 1,635 (CAO amide),
1,602 (CAN imine), 1,597 and 1,458 (CAC aromatic), 1,450 (N-O fu-
roxan). 1HNMR (300MHz, DMSOd6) : 11.98 (1H; s; N-H), 8.31 (1H; s;
C-Himine), 7.77 (2H; dd; Jortho  7.9 Hz and Jmeta  2 Hz), 7.60 (2H; d;
Jortho 7.9 Hz), 7.56 (1H; dt; Jortho 7.9 Hz and Jmeta 2 Hz), 7.22 (2H;
dd; Jortho 8.2 Hz), 6.59 (2H; dd; Jortho 8.2 Hz), 5.89 (2H; s; N-Hamine)
ppm. 13C NMR (75 MHz, DMSOd6) : 164.70, 157.21, 149.87, 131.02,
130.07, 129.70, 129.42, 126.92, 125.02, 121.8, 115.33, 113.41 ppm. Anal-
ysis calculated for C16H13N5O3: C, 59.44; H, 4.05; N, 21.66. Found: C,
59.70; H, 4.19; N, 21.85. LRMS: m/z 324.10 [MH].
Data for 2-amino-N=-[(1E)-(3-oxido-2,1,3-benzoxadiazol-5-yl)
methylene]benzohydrazide (compound 8a) are as follows: yield, 96%;
mp, 202 to 203°C. Rf, 0.57 (1:1 ethyl acetate-hexane). IRVmax (cm
1; KBr
pellets): 3,421 (N-H aromatic), 3,078 (C-H aromatic), 1,622 (CAO
amide), 1,612 (CAN imine), 1,560 and 1,464 (CAC aromatic), 1,450
(N-O furoxan). 1HNMR (300MHz,DMSOd6) : 10.97 (1H; s; N-H), 8.44
(1H; s; C-Himine), 7.66 to 8.22 (3H; m), 7.58 (1H; d; Jortho 8 Hz), 7.22
(1H; dd; Jortho 8Hz/Jmeta 2Hz), 6.78 (1H; d; Jortho 8Hz), 6.58 (1H;
dd; Jortho  8 Hz/Jmeta  2Hz), 6.45 (2H; s; N-Hamine).
13C NMR (75
MHz, DMSOd6) : 165.2, 149.1, 147.2, 133.0, 132.7, 131.0, 129.7, 129.4,
129.2, 128.5, 119.6, 116.7, 115.2, 114.4 ppm. Analysis calculated for
C14H11N5O3: C, 56.56; H, 3.73; N, 23.56. Found: C, 56.77; H, 3.52; N,
23.80. LRMS: m/z 298.09 [MH].
Data for 3-amino-N=-[(1E)-(3-oxido-2,1,3-benzoxadiazol-5-yl)
methylene]benzohydrazide (compound 8b) are as follows: yield, 70%;
mp, 211 to 213°C. Rf, 0.76 (1:1 ethyl acetate-hexane). IRVmax (cm
1; KBr
pellets): 3,431 (N-H aromatic), 3,082 (C-H aromatic), 1,654 (CAO
amide), 1,610 (CAN imine), 1,556 and 1,467 (CAC aromatic), 1,450
(N-O furoxan). 1HNMR (300MHz,DMSOd6) : 10.01 (1H; s; N-H), 8.82
(1H; s; C-Himine), 7.65 to 8.13 (6H; m), 6.73 to 7.15 (3H; m; N-Hamine).
13C NMR (75 MHz, DMSOd6) : 164.7, 148.9, 147.2, 133.8, 133.3, 130.7,
130.2, 129.7, 129.4, 118.6, 117.9, 115.2, 114.4, 112.1 ppm. Analysis calcu-
lated for C14H11N5O3: C, 56.56; H, 3.73; N, 23.56. Found: C, 56.33; H,
3.59; N, 23.64. LRMS: m/z 298.09 [MH].
Data for 4-amino-N=-[(1E)-(3-oxido-2,1,3-benzoxadiazol-5-yl)
methylene]benzohydrazide (compound 8c) are as follows: yield, 98%;
mp, 225 to 227°C. Rf, 0.46 (1:1 ethyl acetate-hexane). IRVmax (cm
1; KBr
pellets): 3,419 (N-H aromatic), 3,080 (C-H aromatic), 1,654 (CAO
amide), 1,627 (CAN imine), 1,550 and 1,461 (CAC aromatic), 1,450
(N-O furoxan). 1HNMR (300MHz,DMSOd6) : 11.80 (1H; s; N-H), 8.45
(1H; s; C-Himine), 7.72 to 8.03 (3H;m), 7.69 (2H; dd; Jortho 7.8Hz/Jmeta
1.9 Hz), 6.50 (2H; dd; Jortho  7.8 Hz/Jmeta  1.9 Hz), 5.87 (2H; s; N-
Hamine).
13C NMR (75 MHz, DMSOd6) : 163.7, 158.9, 152.1, 142.7,
137.9, 129.8, 128.8, 119.4, 115.7, 113.3, 112.4 ppm. Analysis calculated for
C14H11N5O3: C, 56.56; H, 3.73; N, 23.56. Found: C, 56.19; H, 3.88; N,
23.71. LRMS: m/z 298.09 [MH].
General procedure for the synthesis of compounds 13a and -b. A
mixture of 3-hydroxybenzaldehyde or 4-hydroxybenzaldehyde (0.4 g, 3.3
mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 0.5 ml, 3.3 mmol),
and 10 ml of dichloromethane was stirred under nitrogen at room tem-
perature for 20min. Then, 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-N-
oxide (compound 12) (1.0 g, 2,73mmol) was slowly added to the reaction
mixture. The reaction mixture was stirred under nitrogen at room tem-
perature for 2 to 2.5 h and monitored by TLC (1:1, dichloromethane-
hexane). The compounds 13a and -b were isolated by the addition of 50
ml of dichloromethane. Then, the organic phase was washed with satu-
rated potassium carbonate (5 times, 30 ml). The organic phase was dried
with sodium sulfate. After filtration, the organic phase was concentrated
under reduced pressure to produce a yellow solid. The samples were fur-
ther purified with silica gel column chromatography, using dichloro-
methane-hexane (5:4) as themobile phase to give the compounds 13a and
-b as white powder.
Data for 3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy}
benzaldehyde (compound 13a) are as follows: yield, 57%; mp, 102 to
104°C. Rf, 0.1 (1:1 dichloromethane-hexane). IR Vmax (cm
1; KBr pel-
lets): 3,081 (C-H aromatic), 2,762 (C-H aldehyde), 1,697 (CAO alde-
hyde), 1,598 (CAN furoxan), 1,442 (N-O furoxan), 1,560 to 1,450 (CAC
aromatic), 1,357 and 1,165 (SAO sulfone). 1H NMR (300 MHz, CDCl3)
: 10.03 (1H; s; C-Haldehyde), 8.10 (2H; d, Jortho 8.0 Hz), 7.86 (1H; m),
7.83 (3H; t), 7.66 (3H; m) ppm. 13C NMR (75 MHz, CDCl3) : 190.50,
157.80, 153.30, 138.20, 137.82, 135.87, 130.93, 129.87, 128.60, 128,32,
125.76, 119.82, 110.69 ppm. Analysis calculated for C15H10N2O6S: C,
52.02; H, 2.91; N, 8.09. Found: C, 52.06; H, 3.22; N, 7.91. LRMS: m/z
347.03 [MH].
Data for 4-{[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy}
benzaldehyde (compound 13b) are as follows: yield, 33%; mp, 118 to
120°C. Rf, 0.2 (1:1 dichloromethane-hexane). IR Vmax (cm
1; KBr pel-
lets): 3,078 (C-H aromatic), 2,744 (C-H aldehyde), 1,707 (CAO alde-
hyde), 1,599 (CAN furoxan), 1,450 (N-O furoxan), 1,537 to 1,450 (CAC
aromatic), 1,357 and 1,161 (SAO sulfone). 1H NMR (300 MHz, CDCl3)
: 10.03 (1H; s; C-Haldehyde), 8.03 (4H; m), 7.92 (1H; tt; Jortho 9 Hz and
Jmeta  2.9 Hz), 7.75 (2H; tt; Jortho  9 Hz), 7.66 (2H; d; Jortho  9 Hz)
ppm. 13C NMR (75 MHz, CDCl3) : 193.50, 158.90, 158.65, 138.20,
137.80, 135.60, 133.20, 131.60, 130.10, 121.30, 112.90 ppm. Analysis cal-
culated for C15H10N2O6S: C, 52.02; H, 2.91; N, 8.09. Found: C, 51.88; H,
2.73; N, 8.27. LRMS: m/z 347.03 [MH].
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General procedure for the synthesis of compounds 14a to -f.A solu-
tion of 3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy}benzal-
dehyde (compound 13a) (0.3 g, 0.87mmol) or 4-{[5-oxido-4-(phenylsul-
fonyl)-1,2,5-oxadiazol-3-yl]oxy}benzaldehyde (compound 13b) (0.3 g,
0.87 mmol) in 15 ml ethanol containing 5 drops of glacial acid acetic was
stirred at room temperature for 15 min. Later, 2-, 3-, or 4-hydroxybenz-
aldehyde (0.106 g, 0.87 mmol) was added, and the reaction mixture was
stirred under nitrogen at room temperature for 12 h and monitored by
TLC (1:1, ethyl acetate-hexane). The solvent was concentrated under re-
duced pressure, and ice-water was added in order to precipitate the de-
sired products. If necessary, the samples could be further purified with
silica gel column chromatography, using ethyl acetate-hexane (1:1) as the
mobile phase to give the compounds 14a to -f with variable yields (60 to
90%).
Data for 2-hydroxy-N=-[(1E)-(3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-
oxadiazol-3-yl]oxy}phenyl)methylene]benzohydrazide (compound 14a)
are as follows: yield, 90%; mp, 230 to 233°C. Rf, 0.1 (1:1 ethyl acetate-
hexane). IR Vmax (cm
1; KBr pellets): 3,448 (O-H), 3,250 (N-H), 3,082
(C-H aromatic), 1,631 (CAO amide), 1,537 (CAN imine), 1,450 (N-O
furoxan), 1,456 and 1,163 (SAO sulfone). 1HNMR (300MHz, CDCl3) :
11.92 (1H; s;O-H), 11.72 (1H; s), 8.48 (1H; s; C-Himine), 8.08 (2H; d; Jortho
9 Hz), 7.93 (1H; tt; Jortho 9 Hz/Jmeta 1.2 Hz), 7.81 (4H; m), 7.70 (1H;
d; Jortho 9Hz), 7.60 (1H; t; Jortho 9Hz), 7.51 (1H; dd; Jmeta 1.2 Hz),
7.45 (1H; t; Jortho 9 Hz/Jmeta 1.2 Hz), 6.97 (2H; t; Jortho 9 Hz) ppm.
13C NMR (75 MHz, CDCl3) : 164.7, 158.6, 158.5, 152.9, 147.3, 147.1,
136.9, 136.4, 136.3, 130.8, 130.1, 128.8, 128.6, 126.1, 121.5, 119.1,
117.7, 117.3, 116.2, 111.3 ppm. Analysis calculated for C22H16N4O7S:
C, 55.0; H, 3.36; N, 11.66. Found: C, 54.6; H, 3.18; N, 11.29. LRMS:m/z
481.08 [M  H].
Data for 3-hydroxy-N=-[(1E)-(3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-
oxadiazol-3-yl]oxy}phenyl)methylene]benzohydrazide (compound 14b)
are as follows: yield, 85%; mp, 120 to 124°C. Rf, 0.1 (1:1 ethyl acetate-
hexane). IR Vmax (cm
1; KBr pellets): 3,327 (O-H), 3,218 (N-H), 3,080
(C-H aromatic), 1,629 (CAO amide), 1,537 (CAN imine), 1,450 (N-O
furoxan), 1,446 and 1,163 (SAO sulfone). 1HNMR (300MHz, CDCl3) :
11.88 (1H; s; O-H), 9.77 (1H; s; N-H), 8.46 (1H; s; C-Himine), 8.07 (2H;
dd; Jortho 9 Hz/Jmeta 2 Hz), 7.93 (1H; tt; Jortho 9 Hz/Jmeta 2 Hz),
7.78 (3H; m), 7.67 (1H; d; Jortho 9 Hz), 7.58 (1H; t; Jortho 9 Hz), 7.51
(1H; d; Jmeta  1.2 Hz), 7.32 (3H; m), 6.99 (1H; dd; Jmeta  2 Hz).
13C
NMR (75 MHz, CDCl3) : 163.4, 158.5, 157.4, 152.8, 146.2, 136.9, 136.7,
136.2, 134.6, 130.7, 130.0, 129.6, 128.5, 125.8, 121.3, 118.8, 118.2, 117.5,
114.4, 111.2 ppm. Analysis calculated for C22H16N4O7S: C, 55.0; H, 3.36;
N, 11.66. Found: C, 55.3; H, 3.62; N, 11.72. LRMS:m/z 481.08 [MH].
Data for 4-hydroxy-N=-[(1E)-(3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-
oxadiazol-3-yl]oxy}phenyl)methylene]benzohydrazide (compound 14c)
are as follows: yield, 60%; mp, 206 to 210°C. Rf, 0.1 (1:1 ethyl acetate-
hexane). IR Vmax (cm
1; KBr pellets): 3,427 (O-H), 3,224 (N-H), 3,081
(C-H aromatic), 1,653 (CAO amide), 1,537 (CAN imine), 1,450 (N-O
furoxan), 1,454 and 1,165 (SAO sulfone). 1HNMR (300MHz, CDCl3) :
11.70 (1H; s; O-H), 10.16 (1H; s; N-H), 8.44 (1H; s; C-Himine), 8.07 (2H;
dd; Jortho 9 Hz/Jmeta 2 Hz), 7.92 (1H; tt; Jortho 9 Hz/Jmeta 2 Hz),
7.80 (5H; m), 7.65 (1H; d; Jortho 9 Hz), 7.56 (1H; t; Jortho 9 Hz), 7.49
(1H; d; Jmeta  2 Hz), 6.87 (2H; d; Jortho  9 Hz).
13C NMR (75 MHz,
CDCl3) : 160.8, 158.5, 152.8, 149.3, 145.3, 136.8, 135.2, 135.1, 130.6,
130.0, 128.5, 125.7, 123.7, 121.1, 117.4, 115.0, 111.2 ppm. Analysis calcu-
lated for C22H16N4O7S: C, 55.0; H, 3.36; N, 11.66. Found: C, 55.2; H, 3.44;
N, 11.29. LRMS: m/z 481.08 [MH].
Data for 2-hydroxy-N=-[(1E)-(4-{[5-oxido-4-(phenylsulfonyl)-1,2,5-
oxadiazol-3-yl]oxy}phenyl)methylene]benzohydrazide (compound 14d)
are as follows: yield, 90%; mp, 186 to 189°C. Rf, 0.1 (1:1 ethyl acetate-
hexane). IR Vmax (cm
1; KBr pellets): 3,448 (O-H), 3,251 (N-H), 3,083
(C-H aromatic), 1,622 (CAO amide), 1,537 (CAN imine), 1,450 (N-O
furoxan), 1,446 and 1,163 (SAO sulfone). 1HNMR (300MHz, CDCl3) :
11.97 (1H; s; O-H), 10.2 (1H; s; N-H), 8.5 (1H; s; C-Himine), 8.06 (2H; dd;
Jortho 8 Hz/Jmeta 2 Hz), 7.92 (1H; tt; Jortho 8 Hz/Jmeta 2 Hz), 7.90
(3H; m), 7.77 (2H; t; Jortho 8 Hz), 7.54 (2H; d; Jortho 9 Hz), 7.45 (1H;
dd; Jortho 8 Hz/Jmeta 2 Hz), 6.97 (2H; dd; Jortho 8 Hz/Jmeta 2 Hz).
13C NMR (75 MHz, CDCl3) : 164.7, 158.9, 153.8, 143.3, 136.8, 136.1,
133.8, 132.4, 130.0, 128.9, 128.7, 128.5, 120.0, 119.0, 117.2, 116.0, 111.3
ppm. Analysis calculated for C22H16N4O7S: C, 55.0; H, 3.36; N, 11.66.
Found: C, 54.7; H, 3.11; N, 11.38. LRMS: m/z 481.08 [MH].
Data for 3-hydroxy-N=-[(1E)-(4-{[5-oxido-4-(phenylsulfonyl)-1,2,5-
oxadiazol-3-yl]oxy}phenyl)methylene]benzohydrazide (compound 14e)
are as follows: yield, 60%; mp, 201 to 204°C. Rf, 0.1 (1:1 ethyl acetate-
hexane). IR Vmax (cm
1; KBr pellets): 3,410 (O-H), 3,253 (N-H), 3,080
(C-H aromatic), 1,625 (CAO amide), 1,539 (CAN imine), 1,450 (N-O
furoxan), 1,415 and 1,168 (SAO sulfone). 1HNMR (300MHz, CDCl3) :
11.83 (1H; s; O-H), 9.78 (1H; s; N-H), 8.47 (1H; s; C-Himine), 8.06 (2H;
dd; Jortho 8 Hz/Jmeta 2 Hz), 7.90 (1H; t; Jortho 8 Hz/Jmeta 2 Hz),
7.80 (4H;m), 7.52 (2H; d; Jortho 8Hz), 7.32 (3H;m), 6.98 (1H; dd; Jmeta
2Hz). 13CNMR (75MHz, CDCl3) : 163.3, 158.1, 157.4, 153.7, 146.4, 136.9,
136.2, 135.1, 132.7, 130.2, 129.6, 128.5, 128.2, 120.1, 118.8, 118.1, 114.5, 111.3
ppm.Analysis calculated forC22H16N4O7S:C, 55.0;H, 3.36;N, 11.66. Found:
C, 55.2; H, 3.21; N, 11.51. LRMS:m/z 481.08 [MH].
Data for 4-hydroxy-N=-[(1E)-(4-{[5-oxido-4-(phenylsulfonyl)-1,2,5-
oxadiazol-3-yl]oxy}phenyl)methylene]benzohydrazide (compound 14f)
are as follows: yield, 90%; mp, 142 to 145°C. Rf, 0.1 (1:1 ethyl acetate-
hexane). IR Vmax (cm
1; KBr pellets): 3,412 (O-H), 3,253 (N-H), 3,082
(C-H aromatic), 1,626 (CAO amide), 1,539 (CAN imine), 1,451 (N-O
furoxan), 1,415 and 1,168 (SAO sulfone). 1HNMR (300MHz, CDCl3) :
11.69 (1H; s; O-H), 10.12 (1H; s; N-H), 8.44 (1H; s; C-Himine), 8.05 (2H;
dd; Jortho  9 Hz/Jmeta  1.2 Hz), 7.92 (1H; t; Jortho  9 Hz/Jmeta  1.2
Hz), 7.82 (6H; m), 7.51 (2H; d; Jortho 9 Hz), 6.86 (2H; d; Jortho 9 Hz).
13C NMR (75 MHz, CDCl3) : 162.9, 160.7, 158.1, 152.5, 145.9, 136.9,
136.2, 135.2, 132.9, 130.0, 128.6, 128.5, 120.0, 115.0, 111.3 ppm. Analysis
calculated for C22H16N4O7S: C, 55.0; H, 3.36; N, 11.66. Found: C, 55.32;
H, 3.44; N, 11.71. LRMS: m/z 481.08 [MH].
Leishmanicidal activity. (i) Animals. Adult male Swiss albino mice
(20 to 35 g) were used in the experiments. They were housed in single-sex
cages under a 12-h light/12-h dark cycle (lights on at 06:00) in a con-
trolled-temperature room (22  2°C). The mice had free access to food
and water. Groups of two animals were used in each test group. The
experiments were performed after the protocol was approved by the local
Institutional Ethics Committee (protocol number CEUA/FCF/Car no.
53/2012). All experiments were performed in accordance with the current
guidelines for the care of laboratory animals and the ethical guidelines for
the investigation of experimental pain in conscious animals.
(ii) Parasite culture. Promastigotes of L. amazonensis (MPRO/BR/
1972/M1841-LV-79) recently isolated frommiceweremaintained at 28°C
in liver-infusion tryptose (LIT) supplemented with 10% fetal bovine se-
rum (FBS), penicillin (Sigma-Aldrich), and streptomycin (Sigma-Al-
drich).
(iii) Promastigotes. Cultured promastigotes of L. amazonensis at the
end of the exponential growth phase were seeded at 8 106 parasites/ml
in 96-well flat-bottom plates (TPP; Sigma-Aldrich). Compounds, am-
photericin B, and pentamidine (Sigma-Aldrich) were dissolved in DMSO
(the highest concentration was 1.4%, which was not hazardous to the
parasites, as previously determined), added to the parasite suspension to
final concentrations between 0.5 M and 100.0 M, and incubated at
28°C for 72 h. The assays were carried out in triplicate. Leishmanicidal
effects were assessed by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
2H-tetrazolium bromide (MTT)method (28, 29). Absorbances were read
at 490 nm. The drug concentration corresponding to 50%parasite growth
inhibition was expressed as the inhibitory concentration (IC50) in M
(28).
(iv) Cytotoxicity using murine macrophages. To determine the cy-
totoxicity, thioglycolate-stimulated mice were used to collect peritoneal
macrophages. Murine peritoneal macrophages were seeded in 96-well
flat-bottom plates (TPP) at a density of 1 105 cells/well (100l/well) in
RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 25
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mMHEPES, and 2mM L-glutamine and incubated for 4 h at 37°C in a 5%
CO2-air mixture. The medium was removed, and then new medium was
added to the cells, which were treated with different concentrations of
compounds, amphotericin B, and pentamidine (Sigma-Aldrich). Cells
without drugs were used as a negative control. After that, plates were
incubated for 24 h at 37°C in a 5% CO2-air mixture. Subsequently, the
MTT colorimetric assay was carried out as described above. Absorbance
was read in a 96-well plate reader (Robonik) at 595 nm. The drug concen-
tration corresponding to 50% of cell growth inhibition was expressed as
the inhibitory concentration (CC50) (29).
(v) Amastigotes. Murine peritoneal macrophages were plated at 3
105 cells/well on coverslips (13-mm diameter) previously arranged in a
24-well plate in RPMI 1640 medium supplemented with 10% inactivated
FBS and allowed to adhere for 4 h at 37°C in 5% CO2. Adherent macro-
phages were infected with promastigotes in the stationary growth phase
using a ratio of 5:1 L. amazonensis parasites per cell at 37°C in 5%CO2 for
4 h. After that time, the noninternalized parasites were removed by wash-
ing, and infected cultures were incubated in RPMI 1640 medium for 24 h
at 37°C in 5% CO2 to allow parasite multiplication. Then, infected cells
were treated with different concentrations of the compounds, amphoter-
icin B (Sigma-Aldrich), and pentamidine (Sigma-Aldrich) for 24 h. The
cells were then fixed in amethanol solution and stainedwithGiemsa stain.
The number of amastigotes/100 macrophage cells and the percent in-
fected cells were determined. The concentration that caused a 50% de-
crease of growth inhibition compared to the control was determined by
regression analysis and expressed as the inhibitory concentration (IC50) in
M (29).
Nitric oxide production. (i) In vitro studies.A solution of the appro-
priate compound (20 l) in DMSO was added to 2 ml of a mixture of 50
mM phosphate buffer (pH 7.4) and methanol (1:1, vol/vol), containing 5
mM L-cysteine. The final concentration of the compound was 104 M.
After 1 h at 37°C, 1 ml of the reaction mixture was treated with 250 l of
Griess reagent (4 g of sulfanilamide, 0.2 g of N-naphthylethylenediamine
dihydrochloride, 85% phosphoric acid [10 ml] in distilled water [final
volume, 100 ml]). After 10 min at room temperature, the absorbance was
measured at 540 nm using a Shimadzu UV-2501PC spectrophotometer.
Standard sodium nitrite solutions (10 to 80 nmol/ml) were used to con-
struct the calibration curve. The yields of nitrite are expressed as %NO2

(mol/mol). No production of nitrite was observed in the absence of L-cys-
teine (30–32).
(ii) Production in macrophage medium. Culture supernatants from
murine peritoneal macrophages were infected with L. amazonensis and
treated with the compounds 8a and 14a at 17 M and 10.4 M, respec-
tively. Culture supernatants were collected after 48 h, and nitrite produc-
tion was determined using Griess reagent. One hundred microliters of
culture supernatants and 100 l of Griess reagent were pipetted into 96-
well plates and incubated at room temperature for 10 min. Then, absor-
bance was read in a 96-well plate reader (Robonik) at 540 nm (33). The
results, expressed as millimolar concentrations, were determined after
extrapolation of values obtained froma standard curvemadewith sodium
nitrite (NaNO2).Macrophages were used as a negative control whilemac-
rophages infected and not infected with L. amazonensis and treated with 5
g/ml of lipopolysaccharide (LPS) were used as positive controls. All as-
says were performed in triplicate (n 3 experiments).
In vitro stability study. In vitro hydrolysis was performed using the
ultrahigh-performance liquid chromatography (UPLC) method. The
equipment used was a model Acquity H class UPLC (Waters) equipped
with a UV-visible (UV-Vis) detector. The compounds 8a and 14a were
separated in a BEH reverse-phase C18 column (1.7-m particle, 2.1 by 50
mm). The gradient flowwas 30:70 (water-acetonitrile) to 10:10:80 (meth-
anol-water-acetonitrile) in 3min for compound 8a. The gradient flowwas
50:50 (water-acetonitrile) to 70:30 (water-acetonitrile) in 3 min for com-
pound 14a. The flow rate for bothmethods was 0.4ml/min over 6min and
detection at 254 nm. The calibration curvewas linear for compound 8a (r2
0.9990, n 6, 10 to 30 g/ml) and 14a (r2 1, n 6, 20 to 80 g/ml).
For hydrolysis, an appropriate solution of compounds 8a and 14a was
diluted in acetonitrile at 100 g/ml. Then, these solutions were diluted in
buffer (pH 5.4) and water (pH 7.0) to 15 g/ml for compound 8a and 50
g/ml for compound 14a. The samples were subjected to constant agita-
tion in a shaker (137 rpm) at 37°C during the entire assay. The samples
were obtained at the following times: 0, 4, 6, 8, 18, and 24 h. All analyses
were conducted in triplicate, and the results are expressed as the averages
of the concentrations in percentages ( standard error of the mean
[SEM]). The data were analyzed by one-way analysis of variance
(ANOVA), followed by Tukey’s test for multiple comparisons among
groups using the software GraphPad Prism (version 5.01).
RESULTS
Chemistry. The synthetic routes for the preparation of the fu-
roxan (compounds 3, 4a and -b, 13a and -b, and 14a to -f) and
benzofuroxan (compounds 7 and 8a to -c) derivatives are sum-
marized in Fig. 2 and 3.
The compounds 4a and 4b were obtained in three synthetic
steps with an overall yield of 39 to 45%. Cinnamic alcohol was
reacted with sodium nitrite in acetic acid medium to give (2-
FIG 2 Reagents and conditions: (a) NaNO2, CH3COOH, 0°C, 24 h, 90%; (b) pyridinium chlorochromate, CH2Cl2, 25°C, 24 h, 45%; (c) aminobenzohydrazide
derivative, ethanol, Hcat, 25°C, 2 to 4 h, 85 to 98%; (d) NaN3, DMSO, 75°C, 1 h, 99%; (e) toluene, 120°C, 1.5 h, 78%; (f) aminobenzohydrazide derivative,
ethanol, Hcat, 25°C, 2 to 4 h, 85 to 98%.
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oxido-4-phenyl-1,2,5-oxadiazol-3-yl)methanol (step 1). The al-
cohol functionwas oxidized to aldehyde (step 2) using pyridinium
chlorochromate in dichloromethane medium with a yield of 51%
(Fig. 2) (34).
The benzofuroxan (compound 7) and bis-aryl sulfonylfuroxan
(compound 12) derivatives were prepared according to the pro-
cedures previously described (24–27, 33). The 3- or 4-hydroxy-
benzaldehyde was reacted with bis-aryl sulfonylfuroxan (com-
pound 12), using 1,8-diazabicyclo[5.4.0]undec-7-ene as a base, to
give compound 13a or 13b in yields varying between 46 and 57%
(Fig. 3).
The last step to obtain N-acyl hydrazones 4a and -b, 8a to -c,
and 14a to -f involves the coupling reaction between the aldehyde
function and previously selected benzohydrazides (step 3) to ob-
tain the target compounds in excellent yields varying between 85
and 98% (Fig. 2 and 3). The structures of all the compounds were
established by mass spectroscopy, elemental analysis, IR spectros-
copy, and 1H and 13C NMR. All compounds were analyzed by
HPLC, and their purity was confirmed to be over 98.5%. The
analysis of 1H NMR spectra of all acyl hydrazone derivatives
(compounds 4a and -b, 8a to -c, and 14a to -f) has shown a single
signal referring to ylidenic hydrogen attributed to the E-diaste-
reomer (35, 36).
Determination of the IC50. (i) Promastigotes.The leishmani-
cidal activity of the furoxan (compounds 3, 4a and -b, 13a and -b,
and 14a to -f) and benzofuroxan (compounds 7 and 8a to -c)
derivatives was initially determined against L. amazonensis pro-
mastigote forms. The compounds were biologically active against
the parasite in a dose-dependent manner. The aldehyde interme-
diates (compounds 3, 13a and -b, and 7) were very active against
the promastigote form; the IC50s for these compounds ranged
from 0.79 to 4.29 M. However, the selectivity index 1 (SI1) for
the intermediates ranged from 0.38 to 3.61, suggesting that these
aldehydes (compounds 3, 13a and -b, and 7) could cause toxic
effects against macrophage cells. Compounds 8a and 14a to -e
were at least 1.6-fold more active than pentamidine used as a con-
trol against promastigote forms. A remarkable antiprotozoan ef-
fect was observed for compounds 8a and 14a (IC50, 	2.97 M),
which showed higher activity against L. amazonensis than did the
standard drug amphotericin B (IC50, 3.22 M). Compound 14b
has demonstrated activity comparable to that of amphotericin B.
Cytotoxicity studies using murine macrophages have demon-
strated that the intermediate compounds (3, 13a and -b, and 7)
were not selective for the parasite, and the SI1 ranged from 0.38 to
3.61. The selectivity index 1 (SI1) represents the ratio between
CC50 and IC50 for promastigotes. The compounds 8a and 14a to -e
were more selective for the parasite than for mammalian cells (SIs
ranging from7.5 to 38.6). It is worth highlighting that these results
are better than those for the control drugs pentamidine (SI1, 3.5)
and amphotericin B (SI1, 7.16) (Table 1).
(ii) Intracellular amastigotes. Based on the previously ob-
tained data for promastigotes (Table 1), compounds 8a and 14a to
-e, which presented higher SI values than those of the control
drugs pentamidine and amphotericin B, were further evaluated
against intracellular amastigotes. L. amazonensis-infected macro-
phages weremaintained inmedium containing the compounds in
FIG 3 Reagents and conditions: (a) ClCH2COOH, NaOH, H2O, 120°C, 1 h, 95%; (b) acetic acid, H2O2 30%, 25°C, 24 h, 90%; (c) HNO3 red fuming 99%, acetic
acid, 0°C to 110°C, 45min, 45%; (d) hydroxybenzaldehyde, DBU, CH2Cl2, 25°C, 2 to 4 h, 46 to 57%; (e) aminobenzohydrazide derivative, ethanol, H

cat, 25°C,
12 h, 60 to 90%.
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a different range of concentrations (20 to 0.5 M) for a 24-h
period. The compounds 8a, 14a and -b, and 14d were more active
against intracellular amastigotes than was amphotericin B. Com-
pounds 8a and 14a (IC50,	2.16 M) showed more potent antip-
arasitic effects than did amphotericin B and pentamidine (IC50s of
4.92 M and 6.25 M, respectively). The selectivity index 2 (SI2)
represents the ratio between CC50 and IC50 for amastigotes. Fur-
thermore, the SI2s of compounds 8a, 14a and -b, and 14d (SI2,

7.47) showed relevant selectivity for the parasite, compounds 8a
and 14a being at least 6.23-fold less cytotoxic to the mammalian
cells (SI2 values of 29.25 and 54.05, respectively) than were pent-
amidine (SI2, 3.27) and amphotericin B (SI2, 4.69).
Nitric oxide production. (i) In vitro studies. The nitrite pro-
duction from the oxidative reaction of nitric oxide, oxygen, and
water for all compounds (compounds 3, 4a and -b, 7, 8a to -c, 13a
and -b, and 14a to -f) was measured using the Griess reaction
procedure (30–32). This procedure is based on the chemical di-
azotization reaction, which uses sulfonamide and N-1-naphthyl-
enediamine dihydrochloride under acid conditions. The extent of
thiol-induced NO generation was determined after 1 h of incuba-
tion in the presence of a large excess of L-cysteine (1:50). The
results, expressed as percentages of nitrite (NO2
; mol/mol), are
summarized in Table 1. Isosorbide dinitrate (DNS), used as a con-
trol, induced 11.2% of nitrite formation. All furoxan compounds
(compounds 4a, 4b, and 14a to -f) were capable of inducing nitrite
formation in a range between 7.8% and 27.4%. The benzofuroxan
derivatives (compounds 8a to -c) were not able to generate nitrite
in the medium.
(ii) Production in macrophage medium. Culture superna-
tants from murine L. amazonensis-infected peritoneal macro-
phages treated with 17 M and 10.4 M concentrations of the
compounds 8a and 14a, respectively, were collected after 48 h of
incubation, and the nitrite content was determined by the Griess
reaction procedure (26–28). Our results showed that both com-
pounds (8a and 14a) were able to increase nitrite in themedium at
0.75 mM and 1.0 mM (Fig. 4).
In vitro stability study. In order to characterize stability, the
chemical hydrolysis of compounds 8a and 14a was carried out in
aqueous buffer solution (pH 5.4) and water (pH 7.0). The com-
pound 8a has demonstrated stability until 18 h at pH 7.0. In the
acidmedium (pH5.4), this compoundwas stable until 8 h (Fig. 5).
During the experiment, we did not observe the hydrolysis of com-
pound 8a to its parental aldehyde (compound 7). On the other
hand, the furoxan 14a was less stable than was the benzofuroxan
derivative 8a. During the first 4 h, at pH 7.0, the concentration of
compound 14a was reduced by 40%. Compound 14a was imme-
diately cleaved in acid medium (pH 5.4), and the data obtained
TABLE 1 Biological activity of compounds, amphotericin B, and pentamidine against promastigotes and amastigotes of L. amazonensis (IC50);
inhibition of macrophages (CC50); selectivity index (SI); and NO release data
c
Compound
IC50 (g/ml) for
promastigotesa
CC50 (g/ml) for
macrophagesa SI1
IC50 (g/ml) for
amastigotesa SI2
% NO2
 (mol/mol),a,b
L-Cys, 50 104 M
3 1.48 0.11 5.35 0.07 3.61 ND ND 12.3 0.7
4a 67.98 0.34 152.17 2.20 2.24 ND ND 8.2 0.5
4b 95.83 0.65 180.12 25.83 1.88 ND ND 7.8 0.6
7 4.29 0.21 1.62 0.16 0.38 ND ND 0
8a 2.09 0.17 63.18 0.61 30.22 2.16 0.16 29.25 0
8b 163.81 0.77 248.31 2.83 1.52 ND ND 0
8c 40.20 0.33 200.33 2.39 4.98 ND ND 0
13a 0.79 0.01 1.68 0.02 2.13 ND ND 28.2 1.1
13b 0.82 0.05 2.03 0.83 2.47 ND ND 27.8 1.5
14a 2.97 0.18 114.6 4.1 38.58 2.12 0.1 54.05 25.3 1.3
14b 3.21 0.23 32.10 5.83 10.0 4.3 0.52 7.47 24.1 2.6
14c 4.77 0.39 35.83 1.62 7.51 6.33 0.40 5.66 27.4 3.1
14d 4.60 0.37 45.62 1.47 9.91 4.64 0.10 9.83 24.5 2.3
14e 6.43 0.54 208.33 0.17 32.40 8.22 0.27 25.34 26.2 2.7
14f 12.43 0.65 23.54 2.22 1.89 ND ND 25.8 2.4
AmpB 3.22 0.03 23.10 2.52 7.16 4.92 0.14 4.69 0
Pent 10.19 0.85 35.69 6.84 3.50 6.25 0.58 3.27 0
DNS ND ND ND ND ND 11.2 0.8
a Mean standard error of the mean.
b Determined by Griess reaction, after incubation for 1 h at 37°C in pH 7.4 buffered water-methanol mixture, in the presence of a 1:50 molar excess of L-cysteine.
c Abbreviations: DNS, isosorbide dinitrate (DNS possesses two ONO2 groups that may release NO); SI
1, ratio between CC50 and IC50 for promastigotes; SI
2, ratio between CC50 and
IC50 for amastigotes; AmpB, amphotericin B (reference drug); Pent, pentamidine (reference drug); ND, not determined.
FIG 4 NOproduction by Leishmania-infectedmacrophages treated with LPS,
amphotericin B (AmpB), and compounds 8a and 14a at 17 M and 10.4 M,
respectively, compared to control macrophages and macrophages infected
with Leishmania. *, P	 0.05 (Tukey’s test) compared with LPS.
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suggested that total conversion to its parental aldehyde 13a oc-
curred in the first hour (results not shown).
DISCUSSION
The discovery of new, safe, and effective leishmanicidal agents is
urgently necessary since most of the drugs currently in use dem-
onstrate problems that make treatment difficult, such as (i) vari-
able efficacy, (ii) undesirable and serious side effects, (iii) the pres-
ence or induction of resistance to drugs, (iv) the need to be used
during long-term therapy, and (v) high costs (37). Thus, we have
described here the synthesis and leishmanicidal activity of novel
furoxan and benzofuroxan derivatives.
Benzofuroxan and furoxan derivatives have been characterized
as an interesting pharmacophore to antiparasitic activity against
Schistosoma, Mycobacterium, Plasmodium, and Leishmania para-
sites (15–18, 38–41). Specifically, the antiparasitic activity of these
derivatives has been associated with their ability to release NO
(furoxan) or to cause oxidative stress (benzofuroxan).
Promastigote and intracellular amastigote forms ofLeishmania
are both susceptible to NO effects. Exposure of Leishmania infan-
tum promastigotes to exogenous NO donor during log phase di-
minished their infectivity and viability to 75% of the starting val-
ues (42). As Leishmania parasites reside in the form of amastigotes
inside macrophage mammalian cells, the innate and adaptive im-
mune responses are responsible for controlling the infection (43).
The increase in levels of cytokines, such as interferon gamma
(IFN-) and tumor necrosis factor alpha (TNF-), activates in-
ducible nitric oxide synthase (iNOS) to produce NO in a micro-
molar concentration, which kills the parasite (44).
However, as a defense mechanism, phagolysosomal amasti-
gotes decrease NO production in infected macrophages by inhi-
bition of iNOS (45, 46). The iNOS has an important role in Leish-
mania infection. It was demonstrated previously that iNOS
mutant mouse strains were highly susceptible to Leishmania in-
fection (47). SinceNO levels are reduced in infectedmacrophages,
compounds with NO donor ability could help to eliminate intra-
cellular amastigote forms of the parasite.
In fact, NO donors such as S-nitrosothiols have shown leish-
manicidal activity useful in treating cutaneous leishmaniasis.
S-Nitrosoglutathione, for instance, was able to inhibit the
growth of L. amazonensis promastigotes forms with an IC50 of
68.9 M (48). Moreover, S-nitrosoglutathione demonstrated ac-
tivity against intracellular amastigotes and showed a healing effect
on localized cutaneous leishmaniasis lesions caused by L. major
and L. braziliensis in mice (49). Topical treatment of cutaneous
leishmaniasis lesions byNOdonors seems to improve healing and
reduce the number of parasites; however, this beneficial effect is
directly related to the chemical stability of the NO donor com-
pound (49, 50).
The molecular mechanism whereby NO exerts its cytotoxic
activity is not completely understood. Some studies have pro-
posed that NO effects are due to the inhibition of mitochondrial
respiration, glycolysis, peroxidation of membrane lipids, disrup-
tion of Fe-S clusters and zinc fingers, inactivation of peroxidases
and arginases, mutation of DNA, and inhibition of DNA synthesis
and repair (51–53). In addition, S-nitrosylation of some essential
parasite enzymes by NO donors such as S-nitrosoacetylpenicilla-
mine inhibited parasite cysteine proteinase in vivo (54, 55).
The novel furoxan (compounds 4a and -b and 14a to -f) and
benzofuroxan (8a to -c) derivatives presented in this work have
shown leishmanicidal activity against L. amazonensis promasti-
gotes and intracellular amastigotes. In promastigote studies, com-
pounds 3, 7, 8a, 13a and -b, and 14a to -eweremore active than the
standard drug pentamidine. However, compounds 3, 7, and 13a
and -b have demonstrated high cytotoxicity to macrophage cells.
Outstanding leishmanicidal activity was observed for compounds
8a and 14a (IC50,	2.97M),which present SI
1s 4.22 times higher
than that of amphotericin B. However, leishmanicidal activity
against promastigotes does not guarantee activity against intracel-
lular amastigotes, the clinically relevant form of Leishmania spe-
cies. Then, we performed intracellular amastigote studies inwhich
we have found that compounds 8a, 14a and -b, and 14dweremore
active against amastigote forms than were amphotericin B and
pentamidine. All compounds presented good selectivity to the
parasite, with SI2 values greater than 7.47. Notably, compounds 8a
and 14a showed SI2 values of 29 and 54, respectively.
The leishmanicidal activity observed here for furoxan deriva-
tives seems to be related in part to the NO donor ability of these
compounds. In vitro studies for evaluation of NO donor ability
were carried out using the Griess reaction after incubation of all
compounds with a large excess of L-cysteine. The results have
demonstrated that all furoxan compounds were capable of induc-
ing nitrite formation, between 7.8% and 27.4%. The NO donor
ability of furoxan derivatives is directly related to the substitution
in the carbon atom at the 3 position neighboring the N-oxide
FIG5 In vitro stability study. (A)Hydrolytic profile of compound 8a inwater (pH 7.0) and buffer (pH 5.4). (B)Hydrolytic profile of compound 14a inwater (pH
7.0) (data are represented as means SEMs and expressed as %).
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subunit. Furoxan derivatives containing an arylsulfonyl substitu-
tion (compounds 14a to -f) were able to generate nitric oxide at
higher levels than were phenylfuroxan (compounds 4a and -b)
and benzofuroxan (compounds 8a to -c) derivatives, respectively.
The results of furoxan derivatives confirm our previous proposal
that derivatives with an electron-withdrawing substituent at the 3
position, i.e., 3-phenylsulfonyl-substituted derivatives, were bet-
ter NO-releasing compounds than were 3-aryl-substituted furox-
ans (34). Benzofuroxan derivatives (compounds 8a to -c)were not
able to act as NO-releasing compounds in this assay; however,
these compounds seem to induce NO production in the parasite.
It has been reported that some compounds are able to induce
nitric oxide production in infected macrophages, although this
mechanism is not completely understood (56, 57).
Structure-activity relationship studies reveal that in general
bis-aryl sulfonyl derivatives (compounds 14a to -e) are more ac-
tive than phenylfuroxan (compounds 4a and -b) and benzofu-
roxan (compounds 8b and -c). Also, the pattern of substitution of
the benzoyl moiety seems to influence the leishmanicidal activity.
We have observed that ortho substitution (2-hydroxy or 2-amino-
benzoyl) is more potent than meta substitution (3-hydroxyben-
zoyl), which is more potent than para substitution (4-hydroxy or
4-aminobenzoyl). Considering the same NO donor levels during
in vitro studies, these results suggest that not only NO release is
involved in the leishmanicidal activity but also other mechanisms
that need to be further investigated.
It has been described that theN-acyl hydrazone subunit could
be unstable in acid media (58, 59). So, in order to characterize the
chemical stability of the most active compounds, 8a and 14a, we
have performed chemical hydrolysis in vitro. We have studied the
stability at two pHvalues, 5.4 and 7.0. pH5.4was studied due to its
correlation with the pH value of phagolysosome, and pH 7.0 was
studied to characterize the stability of the compounds at neutral
pH. The benzofuroxan derivative 8a has been shown to be stable
for 18 h at pH 7.0 and 8 h at pH 5.4. On the other hand, the
concentration of furoxan 14a at 4 h at pH7.0was found to be 60%.
Compound 14a was very unstable in acidic media, and it was
immediately hydrolyzed at pH 5.4. Interestingly, for this com-
pound we have identified the aldehyde 13a by the UPLC method.
This result suggested that compound 14a could act as a prodrug,
“masking” the aldehyde cytotoxicity toward the macrophage and
facilitating drug permeation across the macrophages and parasite
membranes. Then, in acidic media containing the phagolyso-
some, the compound 14a could be chemically converted, releasing
the aldehyde 13a.
In conclusion, a novel series of furoxan (compounds 4a and -b
and 14a to -f) and benzofuroxan (compounds 8a to -c) derivatives
was synthesized and characterized. The furoxan derivatives (com-
pounds 4a and -b and 14a to -f) have demonstrated nitric oxide
donor properties. The benzofuroxan derivative 8a is able to in-
crease nitrite production in culture supernatants from murine
macrophages infected with L. amazonensis. Among all the com-
pounds that show some selectivity to the promastigote parasite;
the derivatives 8a and 14a to -e have demonstrated good activity
against promastigote forms as well as good selectivity to the para-
site. So, these compounds were selected for further evaluation
against intracellular amastigote forms of L. amazonensis. The re-
sults have shown that compounds 8a, 14a and -b, and 14d were
more effective than amphotericin B. The SI2 values of these com-
pounds were greater than 7.47, while pentamidine and amphoter-
icin B have shown values of 3.27 and 4.69, respectively. Bis-aryl
sulfonyl derivatives (compounds 14a to -e) are more active than
phenylfuroxan (compounds 4a and -b) and benzofuroxan (com-
pounds 8b and -c) derivatives against L. amazonensis amastigotes.
In vitro hydrolysis studies have shown that compound 8a is stable
at pH 5.4 and 7.0 until 8 h and 18 h, respectively. The compound
14a was hydrolyzed 40% in 4 h at pH 7.0. This furoxan derivative
(compound 14a) is unstable at pH 5.4, being immediately hydro-
lyzed. The results presented here highlight the compounds 8a, 14a
and -b, and 14d as novel lead drug candidates for the treatment of
leishmaniasis.
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